PranaX Corporation, a Houston, TX-based biotechnology company focused on regenerative biologics, has raised $17 million in Series A funding.
The Series A round was led by family offices, trusts, and individual investors with substantial experience in biotechnology, regenerative medicine and healthcare innovation.
Read More:Oracle set to raise up to $50 billion in debt and equity this year
The company plans to use the funds to support research and development, expand its infrastructure, strengthen partnerships and accelerate product development and commercialisation.
The financing comes as the exosome wellness sector gains attention as a promising area in regenerative medicine. As demand grows for science-based solutions that support healthy ageing and quality of life, exosomes are increasingly recognised as a key component of next-generation regenerative treatments.
PranaX Corporation is a biotechnology company focused on regenerative biologics. The company develops exosome-based technologies that aim to improve or restore the quality of life and envisions a future where ageing and degeneration are no longer limits to long, fulfilling lives.
“Steven J. Greco, PhD, Founder and Chief Operating Officer of PranaX, said the company was built on the belief that exosomes can change how ageing and long-term wellness are approached. He said PranaX is developing a science based platform that turns biological research into real-world benefits, and that the new funding supports the company’s mission and allows it to grow while staying focused on scientific integrity.”
As PranaX enters its next growth phase, the company stays committed to advancing regenerative biologics through responsible innovation, strong science and a focus on improving quality of life.
About PranaX
Founded in 2022, PranaX is a regenerative biotechnology company focused on using stem cell–derived exosomes, supported by scientific evidence. Its mission is to harness exosomes to support wellness and help people live healthier, more fulfilling lives. The company’s research, development, and manufacturing are based at the Levit Green Life Science Campus in Houston, Texas.
Read More:Outtake Raises $40M in Series B Funding
